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Abstract
Various studies have evaluated the possibilities of surgical repair of mycotic aor-
tic aneurysms (MAAs). Open surgical repair has usually been accepted as the gold 
standard treatment of MAAs. The main concern is that it carries a significant mor-
tality risk, varying from 20 to 40% in different studies, and a 5-year survival rate of 
30–50%. The largest study of open surgical treatment of mycotic aortic aneurysms 
(MAA) was published in 2018, and consisted of 187 patients of whom open repairs 
were performed in 107 patients (57%). Most of the endovascular series conclude that 
endovascular treatment of MAA is feasible and an acceptable alternative treatment 
to open repair. Although endovascular repair might be a durable option for some 
patients, late infection-associated complications frequently occur and are often 
lethal. An overall analysis of this rare pathology, its different diagnostic modalities, 
treatment options, and prognosis are presented and discussed in this chapter.
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1. Introduction
Infected aortic aneurysms, also known as “mycotic aortic aneurysms” (or micro-
bial arteritis with aneurysms) are most commonly caused by bacterial infections. 
Around 1% of arterial aneurysms may be associated with an arterial infection. 
Although the prevalence of mycotic aortic aneurysms (MAAs) is low, its clinical 
impact may be severe and represents one of the most difficult arterial diseases to 
treat successfully.
In the early nineteenth century, Jean Nicolas Corvisart coined the term “vegeta-
tion” as it resembled a cauliflower, describing organic lesions of the heart. In his 
monograph, presented in 1806, Corvisart wrote that he had observed six cases of 
valve disease with vegetations [1].
Some years later, in 1815, Joseph Hodgson performed some illustrations of 
ulcerating/perforating aortic valve endocarditis. He described the valve vegetations 
as “wart-like excrescences” using the term “fungus” in a patient who presented with 
an aortic root abscess. This report was probably the first to document peripheral 
embolization [2].
In 1852, a British physician, William Kirkes, described that fibrinous fragments 
of valve vegetations were found in the kidneys, cerebral artery, and spleen in 
patients presenting with fever, heart murmur, purple skin spots, and skin nodules 
(later called “Osler nodules” by Emanuel Libman). He described how these frag-
ments could be detached from the heart valves, passed into the blood, and may be 
arrested in the aorta or its branches [3, 4].
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The suggestion of an infection point of entry and transportation by blood flow 
was reinforced by a pioneering microbiologist, Edwin Klebs. In 1878, he suggested 
that cases of endocarditis were always due to an infectious organism [5].
The first complete description of an infected aneurysm was presented in 1885 by 
Osler. He presented the first broad report of this entity with a complete description 
of clinical and anatomical features of infective endocarditis as the cause of these 
arterial infections. The report included clinical features, anatomical location in the 
aorta, and cases of “ulcer formation and perforation of the aorta with production of 
multiple aneurysms” [6].
There were some other early reports that explained how infected aortitis was 
nearly always secondary to endocarditis [3, 5, 7, 8]. In another report published 
in 1923, a series of 217 patients with mycotic aneurysms was presented, show-
ing that 86% of mycotic aneurysms were associated with infective endocarditis 
[9]. Although most infected aneurysms are due to bacterial infections, the term 
“mycotic,” which is still misleading, is used to describe these aneurysms that arise 
after an inflammatory destruction of the arterial wall happens associated to arterial 
embolization. A wide variety of terminologies have been used to describe infected 
aortic aneurysms, although most of them have not received a great acceptance. 
Some of these include mycotic aortic aneurysms (MAAs), suppurative arteritis, 
septic aortic pseudoaneurysm (SAP), cryptogenic mycotic aneurysm, and microbial 
arteritis with aneurysms [10–13].
2. Etiology
Table 1 includes a previous classification of infected aneurysms (Table 1) [14]. 
The main etiology of MAAs is considered to be similar to that of arterial aneurysms 
and includes the following:
1. Contiguous infection: an infection localized in a determined area might extend 
and affect the arterial wall. This can happen after bone infections (osteomyeli-
tis and vertebral infections), intraabdominal infections, abscesses, pancreati-
tis, and pancreatic pseudocysts. Arterial aneurysms have been described after 
surgical procedures such as a cholecystectomy, appendectomy, knee replace-
ment surgery, or intestinal surgery [15, 16].
Mycotic 
aneurysm
Infected 
aneurysm
Microbial 
arteritis
Traumatic 
infected 
pseudoaneurysm
Contiguous 
septicemia
Etiology Endocarditis Bacteremia Bacteremia Traumatic Bacteremia
Location Any vessel Distal aorta Aortoiliac Femoral, carotid Aortoiliac
Age 30–50 >50 >50 <30 >50
Sex F > M M M M/F M/F
Incidence Rare Unusual Common Common Unusual
Number Multiple Single Single Multiple Multiple
Bacteriology Gram-
positive cocci
Staphylococcus 
aureus, 
Escherichia coli
Salmonella Polymicrobial
M: Male. F: Female.
Table 1. 
Modified classification of infected aortic aneurysms according to Wilson et al. [14]
3Mycotic Aortic Aneurysms
DOI: http://dx.doi.org/10.5772/intechopen.86328
2. Bacteremic seeding: all arterial layers can be affected by bacteremic seeding, 
which may occur when there is a preexisting aneurysm, atherosclerotic plaque, 
or intimal injury. The intima is usually resistant to infection. Once it becomes 
diseased, bacteria may progress through it into other layers (media or adventi-
tia). As the aorta is the most frequent site of atherosclerosis, it is also the most 
common location of primary arterial infection.
3. Septic embolism: embolization from heart chambers secondary to endocarditis 
(vegetations) can affect the intimal layer or vasa vasorum of vessels, leading 
to arterial wall infection and MAA formation. Embolization may occur in 
between 25 and 50% of patients with endocarditis, but only 1–5% develop 
symptomatic MAAs [17].
4. Direct bacterial inoculation: infected pseudoaneurysms after arterial injuries 
have become a common cause of mycotic aneurysms. The common femoral 
artery (CFA) is the most frequently affected vessel. Vascular trauma, gunshot 
or stab wounds to arteries, intra-arterial drug injection, and iatrogenic arte-
rial injuries can produce a direct inoculation of bacteria into the vessel wall. 
Infected pseudoaneurysms resulting from drug injection using dirty needles 
may involve the CFA, external iliac, subclavian, and carotid arteries [18].
5. Atherosclerosis: MAAs may arise from preexisting aneurysms or atherosclerotic 
plaques.
3. Risk factors
Some important risk factors for development of MAAs include some of the 
following:
1. Infection: other sources of infection are the main cause of MAAs. Still today, the 
most common cause of MAAs is endocarditis, which explains more than 30% 
of cases [17]. The second most common infectious cause of MAAs is bacte-
raemia. Other infections have also been reported and associated to MAAs, 
including cholecystitis, pancreatitis, diverticulitis, urinary tract infections 
(UTI), soft tissue infections, and osteomyelitis.
2. Arterial injuries: previously described in etiology.
3. Immunosuppression: certain diseases and treatments may lead to impaired 
immunity states, including chronic corticoid use, alcohol abuse, diabetes mel-
litus, malignancy, chemotherapy, and severe neutropenia.
4. Epidemiology
Infected arterial aneurysms are relatively uncommon and can affect very differ-
ent anatomical location and practically any artery. Depending on different studies 
presented in the literature, the most common sites for mycotic arterial aneurysms 
are the aorta and the intracranial cerebral arteries. Following Baddour publication 
in 2015, regarding an American Heart Association (AHA) statement report on 
infective endocarditis (IE) in adults, the most common site of mycotic aneurysms 
was the intracranial arteries, with an incidence of 1.5–5% of cases, and an overall 
mortality among those with IE of 60% [17]. Some other series have reported similar 
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findings, with intracranial arteries being the most common site for mycotic aneu-
rysms (especially the middle cerebral artery), with and incidence of symptomatic 
peripheral mycotic aneurysms of 1–5% [19].
Some other reports have published that the higher incidence sites of infected 
aneurysms are the abdominal aorta, followed by peripheral arteries (typically 
occurring at bifurcation sites), cerebral arteries, and visceral arteries, in descending 
order of frequency [20]. On the other hand, previous historical series have reported 
that the abdominal aorta was the second most common site of aneurysm infection, 
with the common femoral artery being the most common site [21].
Mycotic aneurysms of coronary arteries are rare, but have also been described. 
González et al. performed a review including 922 cases of definite infective endo-
carditis (IE), and reported a 2% rate of symptomatic peripheral mycotic aneurysms. 
In their review, 66% of mycotic aneurysms were intracranial (in the region of the 
middle cerebral artery) and 34% were extracranial [19].
With regard to infected aneurysms of the aorta, most reported series have less 
than 50 patients. Most series concur that the most common aortic location for 
infected aneurysms of the aorta is the infrarenal aorta, with a similar distribution of 
cases between the aortic arch and descending aorta.
One of the largest series involving MAAs presented 36 cases of aortic infection, 
with the following epidemiology data: infrarenal aortic aneurysm in 15 patients 
(42%), a suprarenal aneurysm in 3 (8%), a thoracic aneurysm in 5 (14%), and a 
thoracoabdominal (TAAA) in 13 (36%) [22].
A large multicenter European study was published in 2014, where data from 123 
patients with 130 identified MAAs were analyzed. Similar epidemiologic findings were 
found, with infrarenal location being the most common (51%), followed by descending 
MAAs (28%), paravisceral (12%), multiple MAAs (6%), and arch MAAs (3%) [23].
Primary MAAs are a challenging and very complex vascular pathology. Although 
they represent a small proportion of patients within all aortic aneurysms, when left 
untreated, they almost always develop into rupture or lethal complications. Without 
treatment, there is a very high level of lethal complications, including aortic 
rupture, abscess formation, and sepsis [17].
5. Microbiology
With regard to bacteriological patterns in infected aortic aneurysms, there have 
been some changes in bacterial patterns depending on the published series decade. 
Some initial studies on aortic infection have presented their results confirming 
Staphylococcus aureus as the most common infectious cause, followed by Salmonella 
organisms [24]. A series of 17 patients with MAAs reviewed in 1998 presented 
Staphylococcus aureus as the most common responsible organism (29% of patients), 
followed by Salmonella organisms (24% of patients) [25].
This change in bacteriologic patterns was already observed in the early 1980s, 
when comparing those series from before 1965 and those from after 1965. Collected 
series from English language reported before 1984 (178 patients with 243 MAAs) 
showed that S. aureus was the most common organism (28% of cultures), followed 
by Salmonella (15% of aneurysms) and Streptococcus (10% of patients). This series 
reported how there was some alteration in the involved bacterial flora before and 
after 1965. A decrease in the incidence of Salmonella infections was seen after 1965 
(10% compared with 38% prior to that date), as well as an increase in the incidence 
of Staphylococcus aureus (from 19 to 30%) [21].
Some current series have presented a much higher incidence of Gram-negative organ-
isms compared with older series, with Gram-negative microorganisms seen in up to 35% 
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of cases. Different groups have described a higher incidence of aneurysm rupture and 
mortality in those patients with Gram-negative infections compared with Gram-positive 
organisms. Aortic aneurysms with Salmonella-related infections have been associated with 
a faster progression and higher risk of early rupture [23]. Recent series have published an 
increase in Gram-negative bacteria in MAAs, including Salmonella, E. coli, Campylobacter, 
Enterobacter, Serratia, and Proteus [23, 26]. Some of these series have reported even higher 
rates in Gram-negative bacteria (Salmonella) compared to Gram-positive [26–29].
Although bacteriologic patterns continue to evolve, Staphylococcus aureus remains 
the most common pathogen, reported in up to 28–71% of cases [21, 23]. Reports 
from North America and Europe have described Gram-positive Staphylococcus as 
the most prevalent bacterial responsible for MAAs. On the other hand, there are 
reported differences regarding infective organisms depending on the geographic 
area. Many reports from Asia have presented Gram-negative Salmonella species as 
the most prevalent infecting organism in MAAs [23, 27, 28, 30].
Depending on the different series, anatomical location, and geographic area, 
blood cultures have been found to be positive in 50–85% of patients, with organisms 
being able to be isolated from the aneurysmal tissue in 62–76% of patients [23–26].
Some reviews have related mortality with the type of microorganism involved 
in aortic infections. In a series of 22 patients who presented with aortic aneurysmal 
infection, mortality was 36% in those with Salmonella-infected aortas, and 82% 
in those patients with aortic infections due to other microorganisms. Some other 
series have reported similar findings in terms of lower mortality associated with 
Salmonella-aortic infections [23, 27–29].
6. Clinical presentation
Symptoms of mycotic aortic aneurysms are very commonly nonspecific in the 
initial development of the disease. Patients with MAAs often present with fever of 
unknown cause. Many series have reported fever as the most common presenting 
sign of MAAs. These patients with febrile illness frequently present with insidious 
onset, apathy, weight loss, and general malaise [24].
A high index of suspicion is of great importance in order to avoid delay in diag-
nosis, as the natural history of most of these untreated mycotic aortic aneurysms 
is fatality. The most common causes of death in these patients are lethal sepsis or 
massive hemorrhage due to rupture [24, 31].
A vast majority of patients are symptomatic at the time of diagnosis. Most groups 
have outlined rates of MAAs as symptomatic on diagnosis involving 93–100% of 
cases [28, 31]. One of the most common symptoms at the time of initial evaluation 
is localized pain. When present, pain is most commonly localized in the abdomen, 
chest, or back. Some groups have reported pain as the most common initial clinical 
symptom of MAAs, in up to 88% of patients [28, 32]. It has been previously reported 
that the classic triad of mycotic aortic aneurysms includes fever, pulsatile mass, and 
back pain. This triad has been described in around 40% of patients [31].
Other manifestations have been described associated to MAAs, including the 
following:
1. Rupture
Massive hemorrhage may be a sign of MAAs. Some reports have described aortic 
rupture in MAAs in 50–85% of patients [24, 28, 31].
2. Expanding hematoma
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Intraabdominal retroperitoneal hematomas usually produce hypovolemic shock. 
In cases of infected aortoiliac or associated mycotic femoral aneurysms, superficial 
expanding hematomas might be seen.
3. Acute ischemia of the lower limbs
Embolization is a common clinical sign that increases limb loss and mortality 
rates.
4. Mesenteric ischemia
Infected pararenal of thoracoabdominal aortic aneurysms (TAAA) involving 
the superior mesenteric artery (SMA) may cause acute thrombosis of the SMA or 
embolization into the distal mesenteric branches, leading to intestinal ischemia.
5. Osteomyelitis
Infection of the aorta may produce contiguous infection of the lumbar or tho-
racic vertebra. Interchangeably, a bone infection affecting the vertebra may provoke 
an infection of an aortic aneurysm.
6. Gastrointestinal bleeding
Although rare, primary aorto-duodenal fistula may occur due to an infected 
aortic aneurysm, when erosion of the vessel affects the third portion of the duode-
num. Erosion and rupture of a MAA into a gastrointestinal structure, such as the 
esophagus or appendix, have also been described.
7. Intraabdominal abscess
8. Hemoptysis, dysphagia, and hoarseness
Rupture of a mycotic thoracic aortic aneurysm or pseudoaneurysm, or aorto-
bronchial fistula formation may lead to hemoptysis [33].
9. Heart failure
10. Compression
Constriction or displacement of nearby structures may be present due to MAAs.
7. Infected versus inflammatory AAA
Although inflammation is frequently associated with aortic aneurysms, the clas-
sical appearance of an AAA needs to be differentiated from aortic aneurysms that 
are infected. Also mycotic aneurysms need to be addressed and distinguished from 
a clinical entity known as “inflammatory aneurysms.”
Approximately 3–10% of abdominal aortic aneurysms are characterized by 
increased inflammation surrounding the aneurysm. These inflammatory abdomi-
nal aortic aneurysms (IAAA) are typically differentiated from common AAAs by 
certain features. These include a classical description of periaortic inflammation as 
a white gleaming fibrotic surface with a thickened aneurysmal wall [37].
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Other common features of IAAAs include major adhesions and fibrosis of close 
anatomical structures, such as the duodenum and ureters. This fibrosis commonly 
leads to indistinct retroperitoneal tissue planes on imaging studies.
The classic triad of IAAAs includes abdominal pain, weight loss, and elevation 
of inflammatory markers (CRP, ESR). Inflammatory aortic aneurysms are not 
associated with periaortic air or fluid and are not infected (tissue samples and blood 
cultures are negative).
8. Diagnosis
The diagnosis of mycotic aortic aneurysms might be very challenging. In the 
presence of fever, general malaise, and a pulsatile abdominal mass or aortic aneu-
rysm in imaging testing, a MAA should be suspected and investigated. An early 
diagnosis of MAAs is essential as it is associated with a high rate of hemorrhage due 
to rupture and high rate of early sepsis and mortality. Once a MAA is suspected, the 
patient should be investigated with laboratory testing and imaging studies.
Various definitions have been proposed for the diagnosis of mycotic aneurysms, 
including clinical, laboratory and radiological features.
Most series agree that the definition of mycotic aortic aneurysm should include 
at least two of the following criteria:
• Fever, sepsis, or localized pain.
• Abnormal laboratory findings (elevated white cell count: WBC, C-reactive pro-
tein: CRP, or erythrocyte sedimentation rate: ESR).
• Positive blood or aortic tissue cultures.
• Specific radiologic findings, including: periaortic soft tissue air, fluid, or mass, 
saccular/multilobular aneurysm or pseudoaneurysm.
Some groups have used specific definitions to delineate mycotic aortic aneu-
rysms, including all of the following: fever or sepsis, abnormal laboratory findings 
(elevated CRP or white cell count), positive blood cultures, and radiologic studies 
showing a false aneurysm (with or without stranding), periaortic fluid, or air 
around the aorta [34]. Common radiologic (CT and MRI) features of MAAs are an 
irregular aortic wall, a lobulated vascular periaortic mass, and peri-aneurysmal gas/
soft-tissue mass/edema.
Although blood cultures may be negative in around 25–50% of patients, negative 
blood cultures alone are not enough to rule out infected aneurysms, and diagnostic 
testing should be completed.
Ultrasound scanning may be useful in diagnosing the presence of an aortic 
aneurysm, but it is not reliable for specific diagnosis of aortic infection. Digital sub-
traction angiography (DSA), besides being an invasive procedure, is not reliable for 
specific identification of features that suggest and diagnose an infected aneurysm.
Imaging studies for detection of MAAs include computed tomography scan 
(CT) and multislice CT angiography with 3D reconstruction, as well as magnetic 
resonance imaging (MRI). For many groups, MRI with gadolinium enhancement is 
becoming the noninvasive imaging modality of choice for the diagnosis of acute or 
chronic aortitis.
Nuclear medicine studies, including fluorodeoxyglucose-positron emission 
tomography (FDG-PET) and nuclear gallium scanning, are alternative modalities 
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for evaluating mycotic aortic aneurysms that are becoming increasingly useful. 
PET-CT testing has a very high sensitivity and both high positive and negative 
predictive values for aortic graft infection, and also provides important information 
in the diagnosis of mycotic aneurysms [34].
Current imaging studies have reported variable sensitivities regarding FDG-
PET. Most series have published specificities of 88–100% for 18F-FDG PET and 
PET-CT for diagnosing active inflammation in arteritis (Figure 1) [34–36].
There are very few classifications regarding infected aortic aneurysms. The 
author would like to add a new modified classification of MAAs (Table 2).
9. Management of MAAs
9.1 Antibiotherapy
9.1.1 Recommendations
Various groups recommend vancomycin plus an anti-Gram-negative antibi-
otic (for coverage of Salmonella and Gram-negative microorganisms), including 
MAA grade I MAA grade II MAA grade III MAA grade IV
Radiologic findings 1. A. ulcer or
2. A. mass or
3. A. pseudoaneurysm
Grade I and 
periaortic 
edema
Grade I and 
periaortic gas
Grade I and 
rupture (*)
Inflammatory 
markers (CRP and 
ESR)
+ + +++ +++
Aortic tissue — +/− + +
Incidence Rare Very rare Very rare Very rare
Bacteriology Absent Present Present Present
MAA: mycotic aortic aneurysm; A.: aortic; CRP: C-reactive protein; ESR: elevated sedimentation rate; (*): contained 
or not; +: positive; +++: highly positive.
Table 2. 
Ribé’s proposal of new modified classification of MAAs.
Figure 1. 
CT scan showing a reconstruction of a distal infrarenal MAA (A). Fused frontal imaging of the contrast CT 
and FDG-PET scan showing highly elevated FDG uptake in the distal aorta (B).
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intravenous fluoroquinolone, ceftriaxone, and piperacillin-tazobactam. Results of 
blood cultures and tissue samples are monitored for hours or days, until a pathogen 
is correctly identified. Empirical antimicrobial therapy is maintained during this 
time, and reviewed once a pathogen is defined. Antibiotherapy should then be 
tailored to cultures and antimicrobial susceptibility [23, 24, 31].
In general, at least 6 weeks of intravenous plus oral antibiotics should be 
implemented. However, there are no data to support specific duration of antibiotic 
therapy. Several authors have advocated long-term oral antibiotics after hospital 
discharge for all patients undergoing intervention, especially those who underwent 
endovascular repair. If positive cultures are obtained from tissue samples, life-long 
antibiotic therapy should be considered [31, 32, 38, 39].
9.2 Surgery
9.2.1 Excision and ligation without arterial reconstruction
The aneurysm should be dissected back to normal aortic tissue. Once the aneu-
rysm has been resected, the proximal aorta should be oversewn with a nonabsorb-
able suture, ligated 1–2 cm proximally, and possible omental coverage, to prevent 
blowout of the arterial stump.
9.2.2 Excision with immediate revascularization
In those cases where it is likely that the patient may develop acute ischemia 
after arterial ligation, immediate revascularization should be considered. Extra-
anatomical bypass (axillobifemoral bypass graft) after aneurysm resection and 
stump closure has been traditionally used. Autogenous vein, antibiotic, and silver 
impregnated grafts are also used. Other reported options are femoral-popliteal deep 
veins, cryopreserved arterial allografts, and Dacron prosthetic grafts [39–41].
9.2.3 Excision with interval reconstruction
9.2.3.1 Hybrid repair
Some groups have described this technique of retrograde visceral revasculariza-
tion (1, 2, 3, or 4 visceral vessels might be revascularized), followed by TEVAR/
EVAR. The technique is performed through a midline laparotomy incision. When 
using the infrarenal aorta as the inflow vessel, a bifurcated 14 × 7 mm Dacron graft 
is prepared. Two side grafts (usually 6 mm Dacron grafts) are anastomosed to 
the lateral aspect of the bifurcated graft, to create the 4-graft retrograde bypass. 
Correct routing and fashioning of the grafts are crucial to avoid early graft throm-
bosis. The right branch (6–7 mm) is anastomosed to the right renal artery (RA). The 
right 7 mm graft would be anastomosed side-to-end to the coeliac axis (tunneled 
in a retropancreatic position). To avoid graft kinking, the left 7 mm graft is anasto-
mosed in an end-to-side fashion to the SMA in a “lazy C” configuration [42].
9.3 Endovascular
Endovascular repair may be a suitable option for infected aortic aneurysms in 
high-risk patients, when open surgery mortality would be prohibitive. In cases  of 
ruptured MAAs, endovascular repair may be an appropriate alternative, as a definitive 
treatment or until debridement and a final treatment may be performed. There is still 
ongoing controversy in the literature regarding the endovascular option as a main 
therapy or as an alternative [23, 30, 37, 39, 43].
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Procedures are usually performed under epidural or general anesthesia, with 
open exposure of one or both common femoral arteries. In those undergoing 
TEVAR, cerebrospinal fluid (CSF) drainage should be considered in those patients 
with expected long thoracic segment coverage. Coverage of the left subclavian 
artery (LSA) is usually avoided unless completely necessary. Some authors have 
described aneurysm sac drainage after EVAR. The procedure is usually performed 
in a prone position. A 21-G needle is inserted into the aneurysm sac. Following 
dilation, a 14–16 Fr drainage catheter is used to aspirate and send the contents for 
microbiological analysis. Pryluck et al. consider that it might aid to decrease the 
infectious content of the aneurysm sac and effectively prevent late reinfection [44].
10. Prosthetic aortic infection
Although this chapter tries to focus on primary MAAs, infected aneurysms or 
pseudoaneurysms can also occur following prosthetic replacement of the aorta.
The incidence of prosthetic aortic graft infection has been described in 0.5–2% 
of cases, including both early and delayed-onset complications [45]. All these 
prosthetic graft infections are associated with high morbidity and mortality rates. 
As previously described in the chapter, different surgical techniques have been 
described for repair of infected MAAs and aortic graft infection. Removal of all 
infected tissue and infected grafts are essential for a successful result.
Plastic surgery-reassembling procedures have also been described for coverage of 
arterial tissue after reconstruction, especially after infections involving the ascending 
aorta, aortic arch, and descending thoracic aorta. These procedures involve musculo-
cutaneous pedicled flaps using various different muscles (including rectus abdominis, 
pectoralis major, latissimus dorsi, and vastus lateralis muscles) [46]. The application of 
these vascularized muscle and omental flaps by plastic surgeons, in conjunction with 
cardiothoracic and vascular surgeons, might be an important alternative for an adequate 
management of these prosthetic aortic infections. Omental flaps have been previously 
described as the most common applied type of autologous flap for coverage of ascend-
ing aorta, aortic arch, and descending thoracic aortic graft infections. Other options 
for wound closure in cases of infected prosthetic aortic grafts with associated wound 
infection include different types of vacuum-assisted closure (VAC) devices [46].
11. Clinical cases
We present here a report of 3 cases of MAAs treated in our center, with a 
description of the procedural techniques and outcomes.
11.1 Clinical case description
The first patient (JGR) was a 72-year-old male with a medical background of 
smoking, who was evaluated for fever and general malaise. Physical examination 
revealed an expansive abdominal pulsatile mass, with pain on palpation. Laboratory 
testing showed elevation of elevated WBC (22 × 103/μL), and inflammatory mark-
ers (CRP, ESR, and procalcitonin). CT angiogram revealed an infected infrarenal 
AAA, measuring 9.2 cm in diameter, with periaortic edema and gas (Figure 2). 
After cardiac, pulmonary, and renal evaluation, the patient was treated with an 
aorto-aortic silver-coated Dacron bypass graft. Blood cultures were positive for 
Staphylococcus aureus. After an uneventful recovery, he was discharged from 
hospital 10 days after surgery on long-term antibiotics.
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The second patient (ABM) was a 66-year-old male with a medical history of 
chronic obstructive pulmonary disease (COPD), hypertension, and smoking. He 
was initially evaluated in the emergency department for hematochezia, fever, and 
abdominal pain. Physical examination showed a distended abdomen with an abdom-
inal pulsatile mass. Laboratory testing showed markedly elevated inflammatory 
markers, including CRP and ESR. The patient presented sudden rectal bleeding and 
hypotension. Emergent CT angiography scan demonstrated a MAA at the level of the 
infrarenal aorta, with an associated primary aorto-enteric fistula (AEF) Figure 3.
He was taken to the operating room and had an urgent open aortic and small 
bowel repair. An aorto-aortic straight bypass graft, using a silver-coated-Dacron 
graft, was performed. Repair of the fistula into the jejunum was carried out with 
resection of the perforated bowel, and end-to-end anastomosis of a non-affected 
segment of jejunum. A Jackson-Pratt drain was left for 6 postoperative days. Blood 
cultures and aortic tissue sample were both positive for Salmonella sp. The patient was 
kept in the intensive care unit (ICU) for 5 days. After evaluation by the infectious dis-
ease team, he was discharged home on long-term antibiotics 16 days after the surgery.
He had a follow-up at 1, 6, and 12 months. His last CT scan showed no signs of 
aortic infection, without elevation of inflammatory markers on laboratory testing. 
His latest physical examination revealed no vascular abnormalities.
The third patient (RMS) was a 74-year-old male who was admitted with per-
sistent back pain and fever. CT scan revealed a juxtarenal infected aortic aneurysm 
Figure 2. 
Patient 1. Chest computed tomography (CT) scan presenting a 9-cm MAA in the infrarenal aorta. MAA 
compressing (white arrow) the duodenum (A). Sagittal, frontal, and sagittal planes (B). MAA: mycotic aortic 
aneurysm.
Figure 3. 
Patient 2. Abdomen angiography CT scan showing an infrarenal MAA. Multilobular mass seen in axial (A) 
and sagittal (B) planes. Presence of an aortoenteric fistula (AEF) at the site (yellow arrow) of this MAA (C).
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with gas within the aneurysmal sac, measuring 9 cm in diameter (Figure 4). 
Further preoperative MRI-imaging revealed spondylodiscitis at the level of the 
lumbar vertebra L3-L4 (Figure 4).
The patient was taken to the operating room and underwent an aorto-aortic 
straight rifampicin-bonded Dacron bypass-graft. Subsequent aortic wall tissue and 
blood cultures were found to be both positive for Staphylococcus aureus. Intravenous 
antibiotics were continued throughout the admission period and for 3 months after. 
After evaluation of the vertebral osteomyelitis by the orthopedic and microbiolo-
gist teams, he was discharged from the hospital 14 days after surgery on long-term 
intravenous (initially) and oral antibiotics.
Since 2011, we have performed in our center a novel hybrid repair in 2 cases of 
mycotic aortic aneurysms (MAAs), one of them a primary juxtarenal MAA, and 
the other one a suspected inflammatory infrarenal aortic aneurysm. This hybrid 
repair consisted in a two-stage procedure, performed within at least one-month 
difference, or once inflammatory markers and radiologic imaging studies had 
normalized.
The first stage of the procedure consisted in performing an open repair of 
the MAA, with interposition of a cryopreserved arterial allograft. This was done 
in 2 patients who presented with abdominal pain and a pulsatile mass on physi-
cal examination, with a CT angiogram that showed a contained ruptured aortic 
aneurysm in both cases. An aorto-aortic bypass graft using a cryopreserved arterial 
allograft was performed in both cases (Figure 5).
Figure 5. 
Intraoperative images showing the surgical preparation of the arterial aortic cryopreserved allografts (A and B).
Figure 4. 
Patient 3. CT scan revealing a juxtarenal MAA with gas within the aneurysmal sac (B), measuring 9 cm in 
diameter (A). Magnetic resonance imaging (MRI) showing vertebral osteomyelitis (spondylodiscitis) in a 
sagittal plane, with bone erosion (red arrow) at the level of vertebral bodies L3-L4 (C).
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In the second stage, an endoprosthesis (Zenith® stent graft, Cook Medical 
Inc., Bloomington, Indiana, USA) was implanted just below the renal arteries, in 
the infrarenal aorta, 1 month after the procedure in the first patient. In the sec-
ond case, an aortic endoprosthesis (Zenith Flex® stent graft, Cook Medical Inc., 
Bloomington, Indiana, USA) was deployed in the infrarenal aorta, sealing the inside 
of the cryopreserved allograft, 6 months after the initial procedure.
We believe that this alternative option might decrease the risk of rupture of the 
cryopreserved allograft anastomosis, which is a devastating complication of open 
repair of MAAs [23, 41].
12. Discussion
Treatment of aortic infection is still one of the most challenging situations for a 
vascular surgeon to confront.
Open extra-anatomic bypass revascularization combined with extensive 
debridement of all infected aortic and peri-aortic tissues, with excision of the 
infected aorta and oversewing of the non-infected aortic stump has been consid-
ered the standard treatment for aortic infection [22, 26, 31].
Open surgical options include the use of antibiotic-soaked Dacron grafts, cryo-
preserved aortic allografts, and biological bovine pericardial materials. The use of 
the superficial femoral vein (SFV)and femoral or popliteal vein segments have also 
been used as an alternative to in situ reconstructions in aortic infections [26, 32]. 
Revascularizations using vein grafts have the advantage of a potential lower risk of 
infection/reinfection. SFV as an autologous material has shown excellent performance 
in terms of long-term infectious complications. The main disadvantage is that vein 
harvesting is time-consuming. Another possible disadvantage of using the SFV is its 
diameter discrepancy with the aorta, and the possible limitation of vein length. These 
vein reconstructions are also functional and durable on follow-up over time [47–49].
Some groups have presented lower rates of recurrent infection and lower 
morbidity and mortality rates associated with rifampicin-soaked Dacron grafts 
compared to those with untreated grafts [34, 45].
Cryopreserved arterial allografts have the advantage of a higher resistance 
to infection, with low rates of reinfection. Techniques in cryopreservation have 
improved in the last decade, possibly contributing to better outcomes of revascular-
ization using these allografts [34, 41, 50].
MAAs of the ascending aorta and aortic arch, without a past medical history of 
previous cardiac or cardiovascular surgery, are very rare. Macedo et al. reported 
an incidence of 2.6% of MAAs of the ascending aorta after a review of their more 
than 25-year experience with aortic mycotic aneurysms [51]. Descriptions of 
mycotic ascending aortic aneurysms or pseudoaneurysms in the literature are very 
scarce. MAAs of the thoracoabdominal aorta are also less common than those of the 
infrarenal aorta. Previous series have presented an incidence of primary infection 
of the thoracic and thoracoabdominal aorta affecting 0.7–4.5% of aortic aneurysms 
altogether [34]. Mycotic saccular, fusiform, and pseudoaneurysms of the ascending 
and descending thoracic aorta have been described in the literature. Repair of these 
aneurysms may be performed with different techniques, including cryopreserved 
arterial homografts, prosthetic antibiotic-soaked grafts, visceral debranching and 
endovascular stent-graft repairs, bovine pericardium patch grafts, and Dacron 
grafts with biological tissue coverage [34, 45, 52].
The largest series of mycotic aortic aneurysms was presented by Heinola et al. in 
2018. This international multicenter study included 187 patients. In their series, 51 
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patients (27%) were treated with open prosthetic repair, 56 (30%) with a biologi-
cal material, and 80 were treated with EVAR (43%). Overall, open repairs were 
performed in 107 patients (57%) in this group, making this the largest series up 
to date on open aortic repair of MAAs [32]. In their analysis, blood and/or tissue 
culture were positive in 43 (77%) cases, 33 (59%) were positive for non-Salmonella 
infection, and 10 (18%) were positive for Salmonella species. The most common 
registered bacterium on cultures was Staphylococcus aureus (27%). It presented a 
thirty-day survival of 95% (n = 53) and 90-day survival of 91% (n = 51). The overall 
treatment-related mortality was 9% (n = 5) [32].
The second largest study to date of open surgical treatment of mycotic aortic 
aneurysms (MAAs) was published in 2014 by Lin et al., including a group of 77 
patients. In this study group, the in-hospital mortality rate was 10% (8/77) for 
patients who underwent open repair and 25% (2/8) for patients who underwent 
EVAR [27].
The first report of endovascular aneurysm repair of a MAA was reported in 
1998 by Semba et al. They reported no postoperative complications from persistent 
bacteraemia after a 24-month follow up, without postoperative mortality [53]. Since 
then, there have been various case reports and series of cases describing EVAR 
and TEVAR for the treatment of ruptured aortic aneurysms and MAAs and their 
outcomes [23, 30, 37, 38, 39, 53]. These series report favorable results for EVAR/
TEVAR for MAAs, providing a less invasive procedure with low early mortality rates 
[23, 30, 33, 37, 39, 53].
Kan et al. performed a systematic review of outcome after EVAR for the treat-
ment of mycotic aortic aneurysms in 2007. They presented a life-time analysis, 
which reported a 30-day survival rate of 89% +/− 4% and a 2-year survival rate of 
82% +/−5.8%. They performed a multivariate logistic regression analysis, which 
showed that only ruptured aneurysms and fever were significant predictors of 
persistent infection in EVAR after MAAs [38].
The largest series to date on endovascular treatment of MAAs was reported 
in 2018 by Heinola et al. This multicenter-group reported 187 MAAs treated in 6 
different European countries between 2006 and 2016 [32]. Another previous large 
series on endovascular treatment of MAAs was reported in 2012 by Sedivy et al. 
This series included 32 patients, treated during a 15-year period. In this series, 81% 
of patients survived the 30-day postoperative period. A total of 50% survived after 
1-year follow-up and 40% survived after a 3-year follow-up [50]. Table 3 includes 
the most important series regarding MAAs (Table 3) [22–32, 34, 38–41, 54].
Although some of these modern series present promising results, with lower 
30-day mortality for endovascular treatments compared to open surgery, the risk 
of persistent infection and late complications might be higher. Some concerns are 
present in modern literature regarding endovascular repair, as there are still no 
long-term follow-up of these series and there is still an ongoing controversy and 
debate regarding placing a stent-graft in a tissue (aorta) that is still infected.
For some complex thoracoabdominal aortic aneurysms (TAAAs), therapeutic 
options may be scarce. In those cases of symptomatic mycotic TAAAs, there may not 
be enough time to create fenestrated/branched custom-made endovascular stent-
grafts. In order to avoid the high morbidity and mortality rates associated with total 
open surgical repair of these mycotic TAAAs, some groups have advocated for the 
performance of a hybrid aortic repair.
This hybrid repair of type I, II, and III TAAAs consists in performing a visceral 
artery debranching with retrograde revascularization, followed by the implanta-
tions of a thoracoabdominal endovascular stent-graft [42, 55, 56].
Contrary to what happens in the infrarenal abdominal aorta, extra-anatomic 
bypasses are very exceptionally used to repair primary MAAs of the thoracic and 
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thoracoabdominal aorta, or graft infections on those sites. Patients with mycotic 
aneurysms of the ascending aorta or arch may present with different signs and 
symptoms, including persistent fever, fatigue, chest or back pain, dyspnea, pleural 
effusion, and hypovolemic shock in cases of mycotic aortic rupture [57].
MAAs have also reported following heart transplantation and different cardiac 
surgical procedures. Bacterial, viral, fungal, and protozoal infections have been 
described after cardiac transplantation, understanding that these patients under 
immunosuppressive medication are at risk of mycotic aneurysm formation [58]. In 
cases of ascending, arch, or descending thoracic mycotic aneurysms associated with 
severe mediastinitis, surgical techniques for aortic repair include cryopreserved 
arterial homografts, repair with deep or superficial femoral veins, coverage with the 
use of the greater omentum, creation of pedicled muscular flaps for arterial cover-
age, tissue debridement, and sternal re-closure [45, 57, 58].
We described in this chapter 2 cases of a novel hybrid repair of MAAs, includ-
ing a staged hybrid procedure, with a first stage including resection of the infected 
Series Year Number patients Technique Mortality (30-day)
Moneta 1998 17 Open 23%
Soravia-Dunand 1999 10 Open 57%
Oderich 2001 43 Open 21%
Müller 2001 33 Open 36%
Fillmore 2003 10 Open 40%
Kyriakides 2004 15 Open 26%
Dubois 2010 44 Open 18.2%
Kan 2010 41 Open (n = 21) 4.8%
EVAR (n = 20) 5%
Yu 2011 53 Open 23%
Weis-Müller 2011 36 Open 33%
Uchida 2012 23 Open 5%
Sedivy 2012 32 EVAR-TEVAR 18.8%
Huang 2014 43 Open (n = 29) 20%
EVAR (n = 11) 9%
Lin 2014 109 Open (n = 77) 10%
EVAR (n = 8) 25%
Sörelius 2014 123 EVAR-TEVAR 9%
Touma 2014 16 Open-Allograft 28%
Sörelius 2016 132 Open (n = 62) 26%
EVAR (n = 70) 14%
Luo 2017 40 EVAR-TEVAR 10%
Corvera 2018 17 Open-Allograft 6%
Heinola 2018 187 Open (n = 51)
EVAR (n = 80)
Allograft (n = 56)
5%
Open, open surgical repair; EVAR, endovascular aneurysm repair; TEVAR, thoracic endovascular aneurysm repair.
Table 3. 
Largest modern series of mycotic aortic aneurysms (MAAs).
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aneurysm and repair with an aortic cryopreserved arterial allograft, followed by 
a second procedure (once inflammatory markers have decreased and radiologic 
features have normalized) consisting of an aortic stent-graft. We believe that this 
option might minimize the risk of cryopreserved allograft rupture that has been 
previously described in the literature in cases of MAAs. Although there are no 
reports describing this technique, we consider that this might be a feasible alterna-
tive to prevent the risk of aortic rupture.
Long-term surveillance, including physical examination, laboratory assessment 
of inflammatory markers, and imaging studies (incorporating CT angiogram and 
FDG-PET or PET-CT) are critical for evaluation of possible complications and 
prompt decision in case of reinfections.
13. Conclusions
Treatment of mycotic aortic aneurysms (MAAs) remains a real challenge in 
modern vascular surgery. There are currently different treatment options, with 
an immense improvement in endovascular techniques and devices. Despite the 
fact of technological and endovascular improvements, this complex pathology is 
still associated with high morbidity and mortality rates. An early diagnosis and 
interventional procedure (open, hybrid, or endovascular repair) and aggressive 
antibiotic therapy are essential to improve outcomes.
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